Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Lidia V. Lysenko"'
Publikováno v:
Терапевтический архив, Vol 94, Iss 6, Pp 713-717 (2022)
Lupus nephritis (LN) is the most common organ lesion in systemic lupus erythematosus (SLE), developing in 4050% of patients. Due to immunosuppressive therapy, the survival of patients with SLE has increased significantly over the past 50 years, and t
Externí odkaz:
https://doaj.org/article/070636b3a2f0450981aa445ce93bdbcb
Autor:
Natalya V. Chebotareva, Anatoly A. Vinogradov, Alla A. Gindis, Irina N. Bobkova, Wenjing Cao, Lidia V. Lysenko
Publikováno v:
Терапевтический архив, Vol 92, Iss 6, Pp 46-52 (2020)
Chronic glomerulonephritis (CGN) is a disease with a steadily progressing course, which is based on inflammation with the activation of immune cells. The severity of the inflammatory reaction in the kidney tissue is determined by the balance of local
Externí odkaz:
https://doaj.org/article/82a3c8f91cf64e4aacd9cf1c948a8f67
Publikováno v:
Терапевтический архив, Vol 92, Iss 6, Pp 15-22 (2020)
In this article we discussed the current state of monoclonal gammapathy of renal significance (Monoclonal Gammopathy of Renal Significance MGRS) and revealed problems of B-cell clone secreting nephrotoxic monoclonal immunoglobulin identification. We
Externí odkaz:
https://doaj.org/article/59e1c682cb3c4ab99ed2bcd8c92f871a
Autor:
Ludmila Yu. Milovanova, Lidia V. Lysenko (Kozlovskaya), Svetlana Yu. Milovanova, Marina V. Taranova, Vasiliy V. Kozlov, Vladimir A. Reshetnikov, Marina V. Lebedeva, Tatyana V. Androsova, Daria O. Zubacheva, Natalia V. Chebotareva
Publikováno v:
Терапевтический архив, Vol 92, Iss 6, Pp 37-45 (2020)
Cardiovascular calcification (CVC) makes a significant contribution to the manifestation of cardiovascular complications in patients with chronic kidney disease. Early CVC markers are currently being actively studied to optimize cardio-renoprotective
Externí odkaz:
https://doaj.org/article/8e58a2ab6c7d4e45a5229f384d8136af
Autor:
Daria V. Gurova, Natalia V. Chebotareva, Anatoliy A. Vinogradov, Ekaterina V. Stavrovskaya, Lidia V. Lysenko
Publikováno v:
Терапевтический архив, Vol 92, Iss 6, Pp 73-75 (2020)
We present a case with a rare variant of glomerulonephritis, IgM nephropathy, which occurs mainly with nephrotic syndrome. The clinical features of this variant of kidney damage are characterized; the pathogenetic and the transformation of this form
Externí odkaz:
https://doaj.org/article/bb16798586bf4cfebd651d4c9aa0fe69
Autor:
Ludmila Yu Milovanova, Mikhail Yu Shvetsov, Svetlana Yu Milovanova, Lidia V. Lysenko (Kozlovskaya), Elena S. Kamyshova, Marina V. Taranova, Marina V. Lebedeva, Vladimir D. Beketov, Tatyana V. Androsova, Vasiliy V. Kozlov, Vladimir A. Reshetnikov, Sergey V. Moiseev
Publikováno v:
Kidney International Reports, Vol 5, Iss 7, Pp 1118- (2020)
Externí odkaz:
https://doaj.org/article/b4a63cf299ab4148a52f969a3855ff7f
Autor:
Alla Gindis, Irina Bobkova, Natalya V. Chebotareva, Anatoly A. Vinogradov, Wenjing Cao, Lidia V. Lysenko
Publikováno v:
Терапевтический архив, Vol 92, Iss 6, Pp 46-52 (2020)
Chronic glomerulonephritis (CGN) is a disease with a steadily progressing course, which is based on inflammation with the activation of immune cells. The severity of the inflammatory reaction in the kidney tissue is determined by the balance of local
Autor:
Brad H. Rovin, Neil Solomons, William F. Pendergraft, Mary Anne Dooley, James Tumlin, Juanita Romero-Diaz, Lidia Lysenko, Sandra V. Navarra, Robert B. Huizinga, Ihar Adzerikho, Elena Mikhailova, Natalya Mitkovskaya, Sergey Pimanov, Nikolay Soroka, Boris Iliev Bogov, Boriana Deliyska, Valentin Ikonomov, Eduard Tilkiyan, Ruth Almeida, Fernando Jimenez, Faud Teran, Irma Tchokhonelidze, Nino Tsiskarishvili, Maynor Herrera Mendez, Nilmo Noel Chavez Perez, Arturo Reyes Loaeza, Sergio Ramon Gutierrez Urena, Juanita Romero Diaz, Rodolfo Araiza Casillas, Magdalena Madero Rovalo, Stanislaw Niemczyk, Antoni Sokalski, Andrzej Wiecek, Marian Klinger, Olga V. Bugrova, Tatiana M. Chernykh, Tatiana R. Kameneva, Lidia V. Lysenko, Tatiana A. Raskina, Olga V. ReshEtko, Natalia N. Vezikova, Tatiana V. Kropotina, Adelya N. Maksudova, Vyacheslav Marasaev, Vladimir A. Dobronravov, Ivan Gordeev, Ashot M. EssAian, Alexey Frolov, Rosa Jelacic, Dragan Jovanovic, Branka Mitic, Gordana Pekovic, Milan Radovic, Goran Radunovic, Patricia Carreira, Federico Diaz Gonzalez, Xavier Fulladosa, Eduardo Ucar, Shamila De Silva, Chula Herath, Anura Hewageegana, Abdul Latiff Mohamed Nazar, A.W.M. Wazil, Iryna Dudar, Olga Godlevska, Svitlana Korneyeva, ViktoriIa Vasylets, Nataliya Sydor, Mykola Kolesnyk, Samir V. Parikh, Nancy Olsen, Ellen M. Ginzler, James A. Tumlin, Amit Saxena, Ramesh Saxena, Richard Alan Lafayette, William Franklin Pendergraft, Amber S. Podoll, Annie A. Arrey-Mensah, Michael Bubb, Jennifer Grossman, Alejandro I. Oporta, Alireza Nami, Md. Mujibur Rahman, Syed Atiqul Haq, Tak Mao Daniel Chan, Mok Mo Yin Temy, Harold Michael P. Gomez, James Bermas, Bernadette Heizel Reyes, Llewellyn T. Hao, Linda Charmaine Roberto, Eric Amante, Allan E. Lanzon, Jung-Yoon Choe, Tae Young Kang, Yon Su Kim, Seung-Geun Lee, Ji Soo Lee, Jason Choo Chon Jun, Archana Vasudevan, Shue-Fen Luo, Tien-Tsai Cheng, Bancha Satirapoj, Kajohnsak Noppakun
Publikováno v:
Kidney international. 95(1)
Calcineurin inhibitors added to standard-of-care induction therapy for lupus nephritis (LN) may increase complete renal remission (CRR) rates. The AURA-LV study tested the novel calcineurin inhibitor voclosporin for efficacy and safety in active LN.
Autor:
Manisha Sahay, Kalpana S. Mehta, Georgi Abraham, Natalya A. Koziolova, Narina P. Alexeeva, Galina Y. Timokhovskaya, Robert G. Fassett, Elena V. Kolmakova, Elena A. Smolyarchuk, Alexey V. Borsukov, Kirill S. Lipatov, G P Arutyunov, Elena Zakharova, Tarun Kumar Saha, David K. Packham, Olga A. Zagrebelnaya, Coreen Oei, Steven F. Russ, Galina V. Volgina, Dmitry V. Perlin, Simon D. Roger, Vladimir A. Dobronravov, Vyacheslav V. Marasaev, Sanjay Kumar, Lawrence P. McMahon, Gullipalli Prasad, Dmitry A. Zateyshchikov, Lidia V. Lysenko, Brendan M. Johnson, Gordana Olbina, Bruce A. Cooper, Narinder Singh, Richard A. Brigandi, Mark Westerman, Janak de Zoysa, Veerabhadra Guptha, Nicholas B Cross
Publikováno v:
American journal of kidney diseases : the official journal of the National Kidney Foundation. 67(6)
Background Anemia associated with chronic kidney disease (CKD) often requires treatment with recombinant human erythropoietin (EPO). Hypoxia-inducible factor−prolyl hydroxylase inhibitors (PHIs) stimulate endogenous EPO synthesis and induce effecti
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.